{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:30:20Z","timestamp":1782552620467,"version":"3.54.5"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Uterine serous carcinoma (USC) is a rare diagnosis but is associated with high mortality. There are limited data to guide adjuvant treatment decisions in early-stage disease. The purpose of this study is to evaluate the impact of adjuvant therapy on recurrence-free survival (RFS) and overall survival (OS) in early-stage USC. Patients with stage I and II USC treated at a single institution from January 2006 to December 2019 were identified. Demographic, clinicopathologic, treatment, and outcome data were collected. Data were compared using descriptive statistics. Survival analyses were performed using Kaplan-Meier and Cox proportional hazards methods. Ninety-four patients were identified. Median follow-up time was 33.5\u00a0months. The median age was 68\u00a0years (range, 49-87), the majority of patients were White (n\u00a0=\u00a078, 83.0%), and the median BMI was 30.7 (range, 14.2-57.3). Minimally invasive surgical staging was performed in 59.6% of cases (n\u00a0=\u00a056). Most patients had stage IA disease (n\u00a0=\u00a070, 74.5%). Most patients (n\u00a0=\u00a079, 84.0%) received adjuvant therapy, and a majority of patients received a combination of systemic chemotherapy and radiation therapy (n\u00a0=\u00a055, 58.5%), with the most common combination being chemotherapy plus vaginal brachytherapy (n\u00a0=\u00a042, 44.7%). Most patients (n\u00a0=\u00a077, 81.9%) remain without evidence of disease, while 17 patients (18.1%) have recurred. Patients receiving 6\u00a0cycles of adjuvant chemotherapy experienced improved OS (P\u00a0=\u00a0.004) and improved RFS (P\u00a0=\u00a0.02) compared to those receiving no adjuvant chemotherapy. Patients with early-stage USC who received 6 cycles of adjuvant chemotherapy had significantly improved OS and RFS when compared to those patients who did not receive adjuvant chemotherapy.<\/jats:p>\n                  <jats:p>This article is part of a Special Collection on Gynecological Cancer.<\/jats:p>","DOI":"10.1093\/aje\/kwaf008","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T23:18:27Z","timestamp":1736810307000},"page":"198-204","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant therapy in early uterine serous carcinoma"],"prefix":"10.1093","volume":"195","author":[{"given":"Alison A","family":"Garrett","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor H","family":"Orellana","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Medical University of South Carolina , Charleston, SC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thing Rinda","family":"Soong","sequence":"additional","affiliation":[{"name":"Department of Pathology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor A","family":"Rives","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, University of Kentucky , Lexington, KY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Coffman","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]},{"name":"Department of Gynecologic Cancers, Magee-Womens Research Institute , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Buckanovich","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]},{"name":"Department of Gynecologic Cancers, Magee-Womens Research Institute , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]},{"name":"Department of Gynecologic Cancers, Magee-Womens Research Institute , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Allegheny Health Networks , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paniti","family":"Sukumvanich","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Department of Pathology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B","family":"Olawaiye","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, UPMC Magee-Womens Hospital , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"2026010804574299800_ref1"},{"key":"2026010804574299800_ref2","author":"NCCN","year":"2025"},{"issue":"1","key":"2026010804574299800_ref3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"issue":"7447","key":"2026010804574299800_ref4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"1","key":"2026010804574299800_ref5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ygyno.2022.10.024","article-title":"Molecular testing for endometrial cancer: an SGO clinical practice statement","volume":"168","author":"Walsh","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2026010804574299800_ref6","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"issue":"3","key":"2026010804574299800_ref7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1006\/gyno.1994.1208","article-title":"Uterine papillary serous carcinoma: patterns of metastatic spread","volume":"54","author":"Goff","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2026010804574299800_ref8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ygyno.2016.10.016","article-title":"Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: an NRG Oncology\/Gynecologic Oncology Group ancillary analysis","volume":"143","author":"Fader","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"Suppl 2","key":"2026010804574299800_ref9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ijgo.12612","article-title":"Cancer of the corpus uteri","volume":"143","author":"Amant","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"9","key":"2026010804574299800_ref10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"Boer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"21","key":"2026010804574299800_ref11","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026010804574299800_ref12","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"2026010804574299800_ref13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2005.06.012","article-title":"Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy","volume":"98","author":"Kelly","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2026010804574299800_ref14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2015.01.544","article-title":"Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study","volume":"137","author":"Mahdi","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2026010804574299800_ref15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ygyno.2017.03.003","article-title":"Utility of radiation therapy for early-stage uterine papillary serous carcinoma","volume":"145","author":"Cham","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"8","key":"2026010804574299800_ref16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/ijgc-2020-001379","article-title":"Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium","volume":"30","author":"Nasioudis","year":"2020","journal-title":"Int J Gynecol Cancer"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwaf008\/61462773\/kwaf008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/1\/198\/61462773\/kwaf008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/1\/198\/61462773\/kwaf008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:57:51Z","timestamp":1767866271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/195\/1\/198\/7958800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,16]]},"published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwaf008","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,1,16]]}}}